PRESS RELEASE

PUBLICATION OF MASITINIB ADJUSTABLE PHASE 3 CLINICAL STUDY IN ALZHEIMER’S DISEASE IN THE MAGAZINE ALZHEIMER RESEARCH & THERAPY

Paris, 28 February, 2023, 8 o’clock CET

AB Science S.A (Euronext – FR0010557264 – AB) today announced the publication of the results of its positive pivotal phase 3 study (AB09004) of masitinib in mild to moderate Alzheimer’s disease (AD) in the prestigious international peer-reviewed journal Alzheimer’s Research & Therapy [1].

This article entitled ‘Masitinib for mild to moderate Alzheimer’s disease: results from a randomized, placebo-controlled phase 3 clinical trial‘ is freely accessible online via the journal’s website: https://alzres.biomedcentral.com/articles/10.1186/s13195-023-01169-x

Professor Bruno Dubois, Director of the Institute for Memory and Alzheimer’s at Pitié Salpêtrière Hospital in Paris, France, and senior author of this article, commented: “This publication provides the first clinical evidence that targeting innate immune cells is an effective strategy for treating mild to moderate dementia due to probable Alzheimer’s disease. RThe results showed that masitinib at 4.5 mg/kg/dYes can benefit patients significant Slowdown cognitive deterioration compared to placebo. There are very limited treatment options for patients with mild to moderate Alzheimer’s disease and to date no approved disease modifying include therapyit The later phase Population with Alzheimer’s disease. I therefore look forward to continuing the development of masitinib in its confirmatory phase 3 study (AB21004), with the expectation that it might To use this difficult-to-treat population.”

Professor Olivier Hermine, MD, President of the AB Science Scientific Committee and member of the Académie des Sciences in France, said: “Masitinib is a highly innovative drug for Alzheimer’s disease because unlike most drug development research in this indication, masitinib is targeted The Brain innate immune systemincluding mast cells.